Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant tumors. Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant.

Slides:

Advertisements

Similar presentations

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Advertisements

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

Volume 27, Issue 1, Pages (January 2015)

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Effects of SC144 on in vivo ovarian tumor.

Atg7 deficiency has distinct consequences for tumor establishment and maintenance in BrafV600E-driven lung tumors and is associated with the emergence.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

Volume 29, Issue 3, Pages (March 2016)

Fig. 5 Local gel scaffold for T cell memory response.

NrasG12D induces CNS tumors in mice.

Sequencing and PDX technologies for the identification and validation of therapeutic targets in non–V600 mutant BRAF melanoma. Sequencing and PDX technologies.

BRAF inhibitor-resistant BRAF-mutant melanoma cells show increased invasion and metastatic potential. BRAF inhibitor-resistant BRAF-mutant melanoma cells.

Role of HER2 in mediating acquired resistance to EGFR inhibition.

PERK signaling is constitutively activated upon EMT and promotes malignancy. PERK signaling is constitutively activated upon EMT and promotes malignancy.

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

Treatment with MI-773 causes changes in p53 status.

Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Effect of MI-773 dosing on long-term efficacy.

Expression of mutant EGFR and downstream signaling components in tumors of mice at survival endpoint. Expression of mutant EGFR and downstream signaling.

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

Genetic EGFR ablation in K-RAS–mutated lung AC reduces tumor growth

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

Polyclonal lung metastases are seeded by polyclonal circulating tumor cell (CTC) clusters. Polyclonal lung metastases are seeded by polyclonal circulating.

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. A, phospho-protein.

mTORC1 is required to prevent cellular senescence.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

Amppos tumors are a distinct tumor subpopulation.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

Rapamycin decreases PD-L1 expression in lung tumors in vivo.

ONC201 activates an ISR, decreases cyclin D1 expression, and causes an accumulation of cells in G1 in TNBC cells sensitive to the compounds' antiproliferative.

Active AR signaling in enzalutamide-resistant xenograft tumors.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Ketogenic diets combined with fractionated radiation treatment results in decreased immunoreactive PCNA in tumor tissue. Ketogenic diets combined with.

Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo). Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo).

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

HMQ1611 inhibited breast tumor growth in mice.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

Effect of CDV on human SF7796 xenografts in vivo.

The effect of a DIO regimen ± EPA+DHA supplementation on tumor growth.

Pomalidomide decreases fibrosis in the lesion areas of the pancreas of KC mice. Pomalidomide decreases fibrosis in the lesion areas of the pancreas of.

Myc succeeds Akt activation and is required for growth of metastatic prostate cancer. Myc succeeds Akt activation and is required for growth of metastatic.

Increased expression of angiogenic factors and inflammatory cytokines in mice exposed to hypoxia. Increased expression of angiogenic factors and inflammatory.

In vivo effects of TTFields on intradermal tumors in mice.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

PDL192 and inhibit the growth of xenograft tumors.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.

Effects of ZOL treatment on pulmonary metastases.

Posttranslational phosphorylation of p53 by platinum drugs in ovarian tumor cells. Posttranslational phosphorylation of p53 by platinum drugs in ovarian.

GCS-100 selectively kills KRAS-addicted lung tumors.

FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for.

In vivo effect of KIN-193 on PTEN-deficient tumors.

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

Curative effect of W+T treatment in vivo.

TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3 pathway. TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3.

MET activation confers resistance to cetuximab (Cmab) or panitumumab (Pmab) in colon cancer cell lines in vitro and in vivo. MET activation confers resistance.

Fig. 3 Minimal treatment of ETL decreases metastatic burden and prolongs survival in the 4T1 breast carcinoma model after tumor resection. Minimal treatment.

SCLC initiated from pulmonary neuroendocrine cells metastasizes without upregulating NFIB. A and B, Mouse models of SCLC. Rb1flox/flox;Trp53flox/flox;p130flox/flox;R26mTmG.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

AXL knockout does not prevent dormancy.

Presentation transcript:

Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant tumors. Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant tumors. A, photomicrographs showing pEGFR staining in pretreatment and post–vemurafenib-treated tumor samples from a patient who displayed intrinsic resistance to vemurafenib. Scale bar, 100 μm. B, photomicrographs showing H&E and phospho-SFK (pSFK) staining in pretreatment and post–vemurafenib-treated tumors from the patient samples shown in A. Scale bar, 50 μm. C, photomicrograph showing phospho-SFK (pSFK) staining in xenotumors of vemurafenib-resistant tumors grown in NOD/SCID mice and treated with vehicle or dasatinib (75 mg/kg/d orally). Scale bar, 250 μm. D, graph showing phospho-SFK (pSFK) levels in lysates from xenotumors of vemurafenib-resistant tumors grown in NOD/SCID mice and treated with vehicle or dasatinib (75 mg/kg/d orally). The graph shows quantification by densitometry of signals from Western blots (shown below; n = 6 for dasatinib group; n = 8 for vehicle group) using ImageJ Software to quantify the Western blot data. **, P < 0.01. E, growth of vemurafenib-resistant xenotumors in NOD/SCID mice treated with vehicle or dasatinib (75 mg/kg/d orally). Drug treatments commenced when tumors were approximately 200 mm3 and show mean tumor volumes ± SEM (ref. 34; n = 6 for dasatinib group; n = 9 for vehicle group). F, photomicrographs showing H&E and HMB45 staining of a lymph node from vehicle-treated NOD/SCID mouse bearing vemurafenib-resistant tumor xenotumors. Scale bar, 75 mm. G, photomicrographs showing H&E and HMB45 staining of lungs from NOD/SCID mice bearing vemurafenib-resistant tumor xenotumors and treated with vehicle or dasatinib (75 mg/kg/d orally). Scale bar, 75 mm. P, parenchyma; T, tumor. Maria R. Girotti et al. Cancer Discovery 2013;3:158-167 ©2013 by American Association for Cancer Research